European Journal of Surgical Oncology
Volume 36, Issue 3 , Pages 275-280 , March 2010

Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: Clinical patterns and outcome variables

  • A. Kornberg

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 3641 9322677; fax: +49 3641 9322692.
    • ,
  • B. Küpper

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany
    • ,
  • A. Tannapfel

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany
    • ,
  • K. Katenkamp

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany
    • Institute of Pathology, Friedrich-Schiller-University, Jena, Germany
    • ,
  • K. Thrum

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany
    • ,
  • O. Habrecht

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany
    • ,
  • J. Wilberg

      Affiliations

    • Department of General, Visceral and Vascular Surgery Friedrich-Schiller-University, Erlanger Allee 101, D-07740 Jena, Germany

,Accepted 1 October 2009.

References 

  1. Schwarz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:268–276
  2. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221–228
  3. Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  4. Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–1086
  5. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652–659
  6. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor node metastasis classification does not have prognostic power. Hepatology. 1998;27:1572–1577
  7. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol. 2003;21:4329–4335
  8. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150–159
  9. Herrero JL, Sangro B, Quiroga J, et al. Liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001;7:631–636
  10. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524
  11. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403
  12. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005;80:113–119
  13. Roayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?. Clin Liver Dis. 2005;9:315–328
  14. Botha JF, Langnas AN. Liver transplantation for hepatocellular carcinoma: an update. J Natl Compr Canc Netw. 2006;4:762–767
  15. Roayaie S, Frisher JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5cm. Ann Surg. 2002;235:533–539
  16. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534–540
  17. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg. 1998;5:29–34
  18. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. J Hepatol. 2005;43:584–589
  19. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324–331
  20. Hoffmann K, Weigand MA, Hillebrand N, Büchler MW, Schmidt J, Schemmer P. Clin Transpl. 2009;23:1–8
  21. In:  Sobin LH,  Wittekind C editor. TNM classification of malignant tumors. 5th ed. New York: Wiley; 1997;
  22. Trotter JF. Sirolimus in liver transplantation. Transpl Proc. 2003;35:193–200
  23. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation. 2002;73:1565–1572
  24. Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81:1633–1639
  25. Schwartz ME, D'Amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: are the Milan criteria still valid?. Eur J Surg Oncol. 2008;34:256–262
  26. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer. 1991;68:2095–2100
  27. Vivarelli M, Cuccetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248:857–862
  28. Vivarelli M, Cuccetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11:497–503
  29. Haddad EM, McAllister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006;18:CD005161
  30. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:715–722
  31. Zimmermann MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14:633–638
  32. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;15:1162–1168
  33. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005;79:855–857

PII: S0748-7983(09)00470-3

doi: 10.1016/j.ejso.2009.10.001

European Journal of Surgical Oncology
Volume 36, Issue 3 , Pages 275-280 , March 2010

Article Tools

* Image Usage & Resolution